Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $94
Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $94
Needham維持對intra-cellular療法的買入評級，將目標價格上調至94美元
Needham analyst Ami Fadia maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $90 to $94.
Needham分析師Ami Fadia認爲Intra-Cellular Therapies（納斯達克：ITCI）值得買入，並將目標價從90美元提高至94美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。